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Vascular dementia (VaD) is a pathogenetically heterogeneous neuropsychiatric syndrome, 
mainly characterized by cognitive impairment. Among dementias, it is second by incidence 
after Alzheimer’s dementia (AD). VaD biomolecular bases have been poorly characterized, 
but vascular-linked factors affecting the CNS and its functions are generally hypothesized 
to perform a major role, together with cardiovascular and immunological factors. miRNAs, 
which perform critically important biomolecular roles within cell networks, are also found 
in biological fluids as circulating miRNAs (cmiRNAs). We hypothesized that differentially 
expressed (DE) cmiRNAs in plasma from VaD patients could be applied to diagnose VaD 
through liquid biopsies; these profiles also could allow to start investigating VaD molecular 
bases. By exploiting TaqMan Low-Density Arrays and single TaqMan assays, miR-10b*, 
miR29a-3p, and miR-130b-3p were discovered and validated as significantly downregu-
lated DE cmiRNAs in VaD patients compared to unaffected controls (NCs). These miRNAs 
also were found to be significantly downregulated in a matched cohort of AD patients, but 
miR-130b-3p levels were lower in AD than in VaD. A negative correlation was detected 
between miR-29a and miR-130b expression and cognitive impairment in VaD and AD, 
respectively. Receiver operating characteristic curves demonstrated that decreased 
plasma levels of miR-10b*, miR29a-3p, and miR-130b-3p allow to discriminate VaD and 
AD patients from NCs. Furthermore, the concurrent downregulation of both miR-10b* 
and miR-130b-3p in VaD showed an area under the curve (AUC) of 0.789 (p < 0.0001) 
with 75% of sensitivity and 72% of specificity, whereas an AUC of 0.789 (p < 0.0001) 
with 92% of sensitivity and 81% of specificity was found for both in AD. The miRNAs 
profiles reported in this paper pave the way to translational applications to molecular VaD 
diagnosis, but they also should allow to further investigate on its molecular bases.
Keywords: vascular dementia, alzheimer’s dementia, non-coding-rnas plasma profiles, liquid biopsies, 
biomarkers
inTrODUcTiOn
Neurodegenerative diseases (NDs) are a large group of clinically severe and difficult to treat pathologi-
cal phenotypes, which are characterized by neuronal death in different areas of the brain (Ghavami 
et al., 2014). Due to an aging world population, it has been forecast that their prevalence will dramati-
cally increase unless strong measures are applied to prevent their epidemic diffusion (Hebert et al., 
2013; Raz et al., 2015). Dementias are characterized by progressive cognitive decline; they are caused 
TaBle 1 | Demographics of VaD, aD patients, and ncs.
samples 
and controls
gender age MMse
Male Female Mean sD Mean sD
VaD 18 20 82.24 6.58 14.14 5.75
AD 17 23 81.375 4.68 19 4.93
NCs 19 21 81.9 6.18 28.5 1.95
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by various pathological processes, including neurodegeneration 
(Raz et  al., 2015). The National Plan to address Alzheimer’s 
disease classified Alzheimer’s disease-related dementias as (1) 
Alzheimer’s dementia (AD), (2) vascular dementia (VaD), (3) 
dementia with Lewy bodies, (4) frontotemporal dementia, and 
(5) mixed dementias (Jagtap et al., 2015). VaD is further classi-
fied as (a) large-vessel VaD, which includes cortical or subcortical 
multi-infarct dementia and strategic infarct dementia; (b) small 
vessel VaD, including subcortical ischemic dementia and other 
forms of dementia due to specific arteriopathies; (c) hemorrhagic 
dementia; and (d) hypoperfusion VaD (Raz et al., 2015). It has 
been estimated that between 1 and 4% of people aged 65 years 
or more are affected by VaD, whose prevalence is predicted to 
double every 5–10  years past the age of 65 (Raz et  al., 2015). 
Currently, VaD molecular bases have been poorly characterized 
(Montine et al., 2014). It then ensues that differential diagnosis 
with other types of dementia as AD is very difficult to perform 
(Gratten et  al., 2014). This represents an important hurdle for 
developing presymptomatic screening tests and eventually 
designing personalized therapies. It is common knowledge 
that most of our genome is composed of genes encoding RNA 
molecules other than mRNAs: these RNAs, which do not code 
for proteins, are denominated non-coding RNAs (ncRNAs) and 
constitute the genome’s dark matter (Tay et al., 2014). ncRNAs are 
classified as long non-coding RNAs (lncRNAs), if their length is 
>200 nt, or small non-coding RNAs (sncRNAs), if their length is 
≤200 nt (Tay et al., 2014). It has been clearly demonstrated that 
microRNAs (miRNAs, sncRNAs of 22–28 nt) are master regula-
tors of networks and pathways in critically important cellular pro-
cesses (Tay et al., 2014); accordingly, miRNAs have been shown 
to be causally involved in neoplastic and degenerative diseases 
(Geaghan and Cairns, 2014). It also has been discovered that 
miRNAs are present in blood as circulating miRNAs  (cmiRNAs), 
either as cell-free complexes with RNA-binding proteins (e.g., 
Ago-2) or enclosed within membrane-bound vesicles (e.g., 
exosomes) (Jung and Suh, 2014). Since cmiRNAs are traceable 
in biological fluids as serum, plasma, and cerebrospinal fluid 
(CSF), it is not surprising that they have been already exploited 
as molecular biomarkers for diseases affecting CNS (Geekiyanage 
et al., 2012). To date, this approach has not been applied to VaD: 
due to the potential importance of this type of data, we sought 
to characterize plasma miRNAs profiles of VaD patients and to 
compare them with those from a cohort of patients affected by 
AD and from matched control individuals (NCs). This allowed 
the identification of three cmiRNAs (miR-10b*, miR29a-3p, and 
miR-130b-3p) that are significantly downregulated in VaD, the 
characterization of their downstream networks, and the identifi-
cation of a set of target genes that are involved in neurodegenera-
tion and cardiovascular pathology.
MaTerials anD MeThODs
Patient selection
Vascular dementia and AD patients and age-, sex-, and ethnicity-
matched control individuals were recruited at Istituto Oasi Maria 
SS. Troina (Enna, Italy) between January 2000 and December 2010 
(Table 1); plasma miRNAs profiles were analyzed at the University 
of Catania between 2014 and 2015. In total, 118 individuals were 
selected: 38 VaD, 40 AD, and 40 NCs (Table  1). VaD patients 
were identified through NINDS-AIREN criteria (McVeigh and 
Passmore, 2006) and AD patients by NINCDS-ADRDA criteria 
(McKhann et  al., 1984) (Tables  S1 and S2 in Supplementary 
Material). Control individuals (NCs) were hospitalized volun-
teers who did not present VaD, AD nor were affected by other 
neurodegenerative, cardiovascular, and neoplastic diseases. Both 
patients and NCs were Sicilian individuals of Caucasian ethnicity 
and had a low-average educational attainment. Following formal 
written consent, patients underwent venipuncture using dry 
vacutainer tubes; blood samples were centrifuged at 4000  rpm 
for 15 min at 20°C to isolate plasma, which was subdivided into 
aliquots and stored at −80°C until analysis. Ethical approval 
for this study was provided by the Ethics Committee of IRCCS 
Associazione Oasi Maria SS.
extraction of mirnas from Plasma
RNA from 400  μl plasma samples was extracted by using a 
Qiagen miRNeasy Mini Kit according to Qiagen Supplementary 
Protocol (Qiagen, GmbH, Hilden, Germany), which allows the 
purification of small RNAs (including miRNAs) from plasma or 
serum; RNA was eluted with 30 μl volume of elution buffer and 
quantified by spectrophotometry (Rizzo et al., 2015).
rna reverse Transcription and 
Preamplification: mirnas Profiling by 
TaqMan low-Density array
To profile plasma cmiRNAs in VaD patients, we selected and 
matched four of them for sex and age with four NCs. Male/female 
ratio was 1; mean age for VaD was 86.25 and for NCs 87.5; mean 
Mini-Mental State Examination (MMSE) was 19 for VaD and 25 
for NCs. Plasma RNAs (3 μl) were retrotranscribed and preampli-
fied with TaqMan MicroRNA Reverse Transcription Kit Applied 
Biosystems (primers for the RT Megaplex™ RT Primers, Human 
Pool A and Pool B), PreAmp Master Mix, and Megaplex PreAmp 
Primers. We profiled the transcriptome of 754 miRNAs with TaqMan 
Low-Density Arrays (TLDAs), TaqMan Human MicroRNA Array 
v3.0 A and B (Applied Biosystems Life Technologies™, Monza, 
Italy), by utilizing 18 μl of preamplified products. PCRs on TLDAs 
were performed on a 7900HT Fast Real Time PCR System (Applied 
Biosystem, Life Technologies™, Monza, Italy).
TlDas Data analysis
To obtain an accurate miRNAs normalization, we used the global 
median normalization (GMN) method. Similar to microarray 
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analysis, Ct values from each sample were normalized to the 
median Ct of the array (Ragusa et al., 2010). By computing Pearson 
correlation among Ct medians and means of each array and Ct of 
each miRNA, we identified a miRNA that showed an expression 
profile close to the median and mean of TLDAs: miR-191-5p. We 
applied the statistical test significance analysis of microarrays 
(SAM), included in Mev (Multi experiment viewer v4.8.1) statis-
tical analysis software,1 applying a two-class paired and unpaired 
test among ΔCts. A false discovery rate (FDR) <0.15 was chosen 
as filter. Relative quantity (RQ) of miRNAs was calculated by 
applying the 2−∆∆Ct  method.
single TaqMan assays
To validate data from profiling, specific single assays were applied 
to differentially expressed (DE) miRNAs among VaD, AD, and 
NCs, exploiting reverse transcription (Reverse Transcription Kit, 
Applied Biosystem) and Real Time PCR with TaqMan probes. 
miR-191-5p was used for normalization by applying the 2−∆∆Ct  
method.
statistical analysis
All statistical analyses were performed using the MedCalc 
software (Version 15.11.4). T-tests (paired and unpaired) 
were used to compare miRNAs plasma levels among VaD, AD 
patients, and NCs. ΔCts for DE miRNAs respect to endogenous 
control miR-191-5p were used to generate a receiver operating 
characteristic (ROC) curve. Area under the curve (AUC) and 
95% confidence intervals (95% CIs) were calculated to assess 
the accuracy of each parameter (sensitivity and specificity) and 
to find an appropriate cut-off point. Statistical significance was 
established at a p-value ≤0.05.
Target Prediction
Validated targets of DE miRNAs were retrieved from miRTar-
base, release 4.5.2 Target prediction was obtained by intersecting 
the predictions by Starbase v2.03 and DIANA-microT CDS v5.0.4 
Among targets predicted by both tools, we selected those showing 
a miRSVR score ≤−0.1.
Pathway enrichment analysis
Pathway enrichment analysis of validated and predicted targets of 
DE miRNAs was performed with two different tools: Gene Trail5 
and DIANA mirPath v2.0.6 The p values for the biological cat-
egories, obtained with the gene set analysis tool GeneTrail, were 
adjusted by FDR and were considered significant if p < 0.05. The 
functional annotation tool DIANA mirPath v2.0 retrieves both 
experimentally verified miRNAs targets from DIANA-TarBase 
v7.07 as predicted miRNAs targets from DIANA-microT-CDS 
1 www.tm4.org
2 http://mirtarbase.mbc.nctu.edu.tw
3 http://starbase.sysu.edu.cn/
4 http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=microT_CDS
5 http://genetrail.bioinf.uni-sb.de
6 http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=mirpath/index
7 http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index
(see text footnote 3); for pathway enrichment analysis with 
DIANA mirPath, we used only predicted targets by DIANA-
microT-CDS as no validated targets were found for miR-10b-3p 
in DIANA-TarBase. MicroT threshold of 0.8 and p-value <0.05 
(Benjamini–Hochberg correction) were selected.
network analysis
Selected targets and their nearest neighbors were used to con-
struct an interaction network with MiMi Plugin 3.18 in Cytoscape 
v2.8.3.9 Centrality analysis was performed by CentiScaPe Plugin 
v.1.21,10 where parameters of betweenness, closeness, degree, and 
stress were selected to identify the most central nodes. To further 
analyze the biological relevance of nodes, Cytoscape plug-in 
ClueGO v2.1.5 was used to perform functional enrichment 
analysis in Gene Ontology and KEGG pathways.
Target mrnas Quantification from Plasma
We extracted mRNA from 400 μl plasma by using Trizol puri-
fication protocol; mRNAs encoding CCT5, GSK3 (targets of 
miR-10b*), BACE1, LPL, NAV3 (targets of miR-29a), EDN1, 
ITPR1, and ZEB-1 (targets of miR-130b) were amplified through 
Power Sybr Green One-Step Real Time PCR (Life Technologies), 
following the manufacturer’s protocol. GPDH was used as 
housekeeping gene. Primers sequences are reported in Table S3 
in Supplementary Material.
resUlTs
identification of De cmirnas in VaD
In the discovery phase of our project, we applied TaqMan Low-
Density Array technology to profile the levels of 754 miRNAs 
in plasma from 4 VaD patients and 4 matched NCs. This led 
to the identification of 13 potentially significant DE miRNAs 
(Table 2): among these, we focused our validation analysis on 
the most dysregulated miRNAs that were endowed with qualita-
tively good amplification curves. In particular, miR-886-5p and 
886-3p showed apparently significant overexpression in VaD 
compared to NCs, whereas miR-10b* (alternative nomenclature: 
miR-10b-3p), miR-29a-3p (alternative nomenclature: miR-29a), 
and miR-130b-3p (alternative nomenclature: miR-130b) showed 
significant underexpression. In the validation phase of our 
work, we extended our analysis to the whole cohort of 38 VaD 
patients and 40 NCs. Single assays for each miRNA confirmed 
that indeed miR-10b*, miR-29a-3p, and miR-130b-3p are all 
significantly underexpressed in plasma from VaD patients with 
respect to NCs (Figure 1). Overexpression of miR-886-5p and 
miR-886-3p did not stand this further statistical test. Expression 
of miR-10b*, miR-29a-3p, and miR-130b-3p was then evalu-
ated in plasma from 40 AD patients, matched by gender, age, 
and ethnic background with the 38 VaD patients and 38 NCs 
previously analyzed. This allowed us to discover that all three 
miRNAs were DE in a statistically significant manner among the 
8 http://chianti.ucsd.edu/cyto_web/plugins/displayplugininfo.php?...MiMIplugin
9 www.cytoscape.org
10 http://apps.cytoscape.org/apps/centiscape
FigUre 1 | Box plot of mir-10b* (a), mir-29a-3p (B), mir-130b-3p  
(c) expression. Validation was by single TaqMan assays in VaD patients 
compared to AD and NCs, and in AD compared to NCs. Values on the 
y-axis are reported as ΔCt × (−1). Samples analyzed: 38 VaD, 40 AD, and 
40 CN. Statistical significance was evaluated by paired T-test.
TaBle 2 | list of differential expressed mirnas in VaD vs. ncs identified 
by TaqMan low-Density arrays.
mirnas rQ
hsa-miR-103 0.18
hsa-mir-10b* 0.35
hsa-mir-130b 0.27
hsa-miR-142-5p 0.57
hsa-miR-143 0.29
hsa-miR-145 0.77
hsa-miR-181c 0.45
hsa-miR-185 2.61
hsa-miR-223 0.48
hsa-miR-26b 0.37
hsa-mir-29a 0.22
hsa-mir-886-3p 3.47
hsa-mir-886-5p 3.04
In bold are miRNAs selected for Single TaqMan assays. RQ, relative quantity. False 
discovery rate <0.15.
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different cohorts (Figure 1). miR-10b* was underexpressed in 
VaD and AD compared to NCs, while its plasma levels were not 
significantly different in the comparison between VaD and AD 
patients (Figure 1A). A similar expression trend was observed 
in the analysis of miR-29a-3p for all types of comparison 
(Figure 1B). On the other hand, miR-130b-3p was significantly 
underexpressed in VaD and AD plasma compared to NCs, but 
in AD patients its expression levels were lower than in VaD 
(Figure  1C). We calculated the mathematical correlation (i.e., 
Pearson and Spearman coefficients) between miRNAs expres-
sion (ΔCt) and MMSE from patients and healthy controls. 
Through this analysis, we found a statistically significant nega-
tive correlation between miR-29a expression and MMSE in VaD 
patients (Pearson = −0.28, p-value = 0.011; Spearman = −0.23 
p-value  =  0.04), and between miR-130b expression and 
MMSE in AD patients (Pearson  =  −0.28, p-value  =  0.011; 
Spearman = −0.29 p-value = 0.009).
rOc curves
By computing ROC curves, we found that the decrease of 
miR-10b*, miR-29a, and miR-130b plasma levels was able to 
discriminate VaD and AD patients from NCs. Specifically, 
we obtained for miR-10b* in VaD, an AUC of 0.63 (95% CI, 
0.507–0.759; p = 0.03) with 78% of sensitivity and 42% of speci-
ficity (ΔCt cut-off value: >1.73); for miR-29a in VaD, an AUC 
of 0.63 (95% CI, 0.507–0.759; p = 0.03) with 76% of sensitivity 
and 41% of specificity (ΔCt cut-off value: >1.05); for miR-130b 
in VaD, an AUC of 0.65 (95% CI, 0.520–0.769; p = 0.02) with 
68% of sensitivity and 53% of specificity (ΔCt cut-off value: 
>−0.62) (Figure  2A). By performing the same analysis with 
data from AD patients, we obtained for miR-10b*, an AUC of 
0.64 (95% CI, 0.520–0.769; p =  0.02) with 74% of sensitivity 
and 48% of specificity (ΔCt cut-off value: >2.14); for miR-29a, 
an AUC of 0.64 (95% CI, 0.520–0.769; p =  0.02) with 75% of 
sensitivity and 41% of specificity (ΔCt cut-off value: >1.05); for 
miR-130b, an AUC of 0.74 (95% CI, 0.620–0.850; p >  0.0001) 
FigUre 2 | receiver operating characteristic (rOc) curves for mir-10b*, mir-29a-3p, and mir-130b-3p in VaD and aD patients. ROC curves of 
miR-10b*, miR-29a-3p, and miR-130b-3p ΔCts in VaD (a) and AD (B). (c) ROC curve of miR-130b-3p ΔCts for discrimination of VaD patients from AD ones. Red 
curve represents ΔCts calculated by using miR-191-5p as endogenous control.
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with 87% of sensitivity and 61% of specificity (ΔCt cut-off value: 
>−0.43) (Figure 2B). Moreover, we calculated a ROC curve also 
for evaluating the discriminatory power of miR-130b in VaD 
patients with respect to those with AD: an AUC of 0.65 (95% 
CI, 0.530–0.780; p =  0.01) with 70% of sensitivity and 46% of 
specificity (ΔCt cut-off value: ≤0.91) was obtained (Figure 2C). 
To improve the potential diagnostic power of DE cmiRNAs, we 
also computed ROC curves for every pair of cmiRNAs: the best 
score in terms of sensitivity and specificity was obtained for the 
couple miR-10b*–miR-130b, which showed for VaD an AUC of 
0.789 (95% CI, 0.636–0.90; p < 0.0001) with 75% of sensitivity 
and 72% of specificity (Figure  3A), whereas an AUC of 0.789 
FigUre 4 | statistical overrepresented Kegg pathways, identified by geneTrail, and target genes included in each Kegg category.
FigUre 3 | rOc curves for couple mir-10b*–mir-130b-3p in VaD and aD patients. ROC curves computed by considering together miR-10b* and 
miR-130b-3p ΔCts for detecting VaD patients (a) and AD patients (B).
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(95% CI, 0.783–0.971; p < 0.0001) with 92% of sensitivity and 
81% of specificity was found for AD (Figure 3B).
Pathway analysis
To pinpoint the biomolecular functions of these DE miRNAs, we 
analyzed their mRNAs targets. This identified (A) 55 predicted 
targets of miR-10b*, (B) 43 validated and 9 predicted targets of 
miR-29a-3p, and (C) 7 validated targets and 14 predicted targets 
of miR-130b-3p (Table S4 in Supplementary Material). By exploit-
ing CentiScaPe Plugin, we reconstructed a network of 2149 nodes 
and 23704 edges: among the 225 nodes, which were discovered 
to be central for all selected parameters, 14 were either validated 
or putative targets of DE miRNAs (Table S5 in Supplementary 
Material). Through GeneTrail Pathway Enrichment Analysis, 
we discovered that target genes of miR-10b*, miR-29a-3p, and 
miR-130b-3p are enriched in each subcategory of eight non-
neoplastic KEGG pathways (Figure 4). Interestingly, the follow-
ing subcategories resulted overrepresented also by using DIANA 
mirPath v2.0 functional annotation tool: axon guidance, focal 
adhesion, neurotrophin signaling pathway, Wnt signaling pathway 
(Figure  2). According to ClueGO, the most involved KEGG 
pathways are cell cycle, focal adhesion, FoxO signaling, hepatitis B, 
insulin signaling, MAPK signaling, neurotrophin signaling, Rap1 
signaling, T cell receptor signaling; three of these (focal adhesion, 
MAPK signaling, and neurotrophin signaling) were also identified 
through GeneTrail. Among the mRNAs targets of miR-10b*, 
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miR-29a-3p, and miR-130b-3p, which were analyzed in plasma 
from VaD and AD patients and NCs (i.e., BACE1, CCT5, EDN1, 
GSK3B, ITPR1, LPL, NAV3, and ZEB1), only ZEB1 (target of 
miR-130b-3p) was detected; however, its plasma levels were not 
different among the individuals of the three cohorts analyzed.
DiscUssiOn
mirnas as VaD Molecular Biomarkers
The important biomolecular roles played by miRNAs within 
organisms at all levels of the evolutionary scale have been dem-
onstrated (Zheng et  al., 2016). Many miRNAs are enriched in 
specific organs, tissues, and cell types, for instance, in different 
areas of the brain or in specific subcompartments of neurons (e.g., 
axons, dendrites, and synapses) (He et al., 2012). cmiRNAs have 
been detected in plasma, serum, whole blood, urine, saliva, sweat, 
breath, and cerebrospinal fluid (Li and Zhang, 2015). Because 
of their small molecular size compared to proteins, cmiRNAs 
cross biological barriers (e.g., blood/brain, blood/placenta); 
they also are present within exosomes isolated from body fluids 
(Li and Zhang, 2015). cmiRNAs have been already exploited as 
biomarkers for depression, bipolar disorder, schizophrenia, and 
Alzheimer’s disease (Ha, 2011), but not for VaD. VaD is thought 
to be caused by diminished cerebral blood flow leading to hypoxia 
and blood–brain barrier altered permeability: vasculotoxic and 
neurotoxic effects ensue, which may promote neurodegeneration. 
VaD may be caused by different pathological events as stroke, 
cerebral hemorrhage, traumas, chronic diseases as atheroscle-
rosis, large and small vessel disease, and cardioembolic disease 
(Iadecola, 2013). It is frequently associated with diabetes, hyper-
tension, hypercholesterolemia, and smoking. In contrast to AD, 
VaD genetic bases are not well defined (Montine et al., 2014). Due 
to the high compensatory potential of the brain, both AD and 
VaD are characterized by late clinical manifestations (Raz et al., 
2015). This delay clearly calls for early activation of diagnostic 
presymptomatic and preventive procedures: when the disease 
becomes clinically evident, pharmacological intervention may 
no longer be very effective (Hebert et al., 2013; Raz et al., 2015). 
Diagnostic criteria for AD and VaD, based on clinical evaluation 
of cognitive decline and deterioration of functional abilities, have 
been proposed by (1) the Diagnostic and Statistical Manual of 
Mental Disorders, Fifth Edition (DSM-5) (Regier et al., 2009), (2) 
the International Classification of Diseases (ICD-10), (3) the USA 
National Institute of Neurological Disorders and Stroke and the 
Association Internationale pour la Recherche et l’Enseignement 
en Neurosciences (NINDS-AIREN) (McVeigh and Passmore, 
2006), (4) the MMSE (Folstein et al., 1975), and (5) the California 
Alzheimer’s Disease Diagnostic and Treatment Centres (CAD-
DTC) (Chui et al., 1992). Moreover, the most recent applications 
of magnetic resonance imaging (MRI) and computed tomogra-
phy (CT) make possible to analyze in detail the brain structure 
and confirm the diagnosis of cerebrovascular diseases as VaD 
(Van Straaten and Stam, 2013). We propose that the molecular 
data reported in this paper nicely complement the diagnostic 
approaches synthesized above: in fact, our data show that miR-
10b*, miR-29a-3p, and miR-130b-3p are DE in plasma from VaD 
patients with respect to NCs. They also are underexpressed in 
plasma from AD patients with respect to NCs, but the levels of 
miR-130b-3p are lower in AD than in VaD patients (Figure 1B). 
A negative correlation exists between miR-29a ΔCt and MMSE 
in VaD, as between miR-130b ΔCt and MMSE in AD. These data 
showed that plasma levels of these two miRNAs decreased as the 
cognitive impairment increased, suggesting a hypothetical link. 
ROC curve analysis suggests that these miRNAs could be con-
sidered useful markers to diagnose VaD and AD. miR-130b levels 
were also able to discriminate VaD from AD with 70% of sensitiv-
ity and 46% of specificity. Intriguingly, by considering the diag-
nostic efficiency of different pairs of cmiRNAs, we found that the 
concurrent downregulation of both miR-10b* and miR-130b-3p 
improved their discriminatory power of VaD and AD patients. 
Accordingly, miR-10b*, miR-29a-3p, and miR-130b-3p are all to 
be considered good markers of VaD and AD (and of neurodegen-
eration in general), but miR-130b-3p may be specifically exploited 
as a differential diagnostic marker between VaD and AD. We 
found in literature no previous mention of circulating or cellular 
miR-10b* related to pathological or physiological conditions. On 
the other hand, decreased levels of miR-29a in serum and whole 
blood of AD patients were previously reported (Geekiyanage 
et al., 2012; Leidinger et al., 2013). Recently, a meta-analysis of 
cmiRNAs deregulated in AD and MCI from 18 independent 
published reports was published: the downregulation of miR-
29a in serum or plasma from AD patients was reported by four 
independent papers, and in two of them its deregulation resulted 
statistically significant (Wu et al., 2015). The authors concluded 
that the inconsistence of results across different studies should 
be the consequence of multiple biological and technical factors. 
miRNAs expression could be influenced by age, genetic variations 
related to ethnicity, environmental factors, comorbid conditions, 
and by biological source of miRNAs (e.g., serum or plasma), 
sample preparation, analysis platform, normalization method, 
and statistical approaches. Notably, about 40% of papers reporting 
data on cmiRNAs in AD and MCI were studies on Chinese popu-
lation (Wu et al., 2015). An altered expression of miR-130b was 
reported in oxidatively stressed primary hippocampal neurons 
and different strains of senescence-accelerated mice, suggesting 
its potential role in the pathogenesis of NDs (Zhang et al., 2014). 
Xie et al. (2015) assayed levels of miR-130b and other AD-related 
miRNAs in serum of patients with mild cognitive impairment 
(MCI); based on their results, miR-130b was not deregulated in 
MCI patients with respect to normal controls.
circulating mirnas in VaD, Their 
Downstream mrna Targets, and 
corresponding gene network
We hypothesized that DE cmiRNAs detected in our experi-
ments could shed a light on the genes and pathways involved 
in VaD, which remain still elusive. Indeed, our computational 
analysis on validated and predicted miRNA targets allowed us 
to discover that miR-10b*, miR-29 family, and miR-130b-3p 
perform important functions in regulating CNS activity and also 
are involved in neurodegenerative and cardiovascular diseases: it 
is worth to stress that both CNS and cardiovascular system are 
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involved in VaD. Among miR-10b* targets, Glycogen synthase 
kinase3-β (GSK3β) is involved in mechanisms underlying learn-
ing and memory. It also is involved in local responses to cerebral 
inflammatory processes (Llorens-Martín et al., 2014). Moreover, 
GSK3β overexpression inhibits brain-derived neurotrophic 
factor (BDNF)-mediated survival pathway (Liu et  al., 2015). 
GSK3β is comprised in six and four of the pathways listed by 
the DIANA mirPath and GeneTrail, respectively (Figure  3). 
The miR-29 family comprises three members (i.e., miR-29a, 
miR-29b, and miR-29c) that have important roles in both nervous 
and cardiovascular systems (Kriegel et  al., 2012). A significant 
negative correlation was detected between miR-29a-3p and Aβ42 
peptide in CSF and blood from AD patients (Hébert et al., 2008). 
Expression of miR-29a/b-1 cluster was found to be significantly 
decreased in AD patients, coupled to abnormally high levels of 
BACE1 protein (Hébert et al., 2008). Similar correlations between 
expression of this miRNA cluster and BACE1 were found during 
brain development and in primary neuronal cultures (Hébert 
et al., 2008). Notably, our data showed significant negative corre-
lation between miR-29a expression and cognitive impairment in 
VaD patients. Neuron navigator 3 (NAV3), involved in axon guid-
ance, is a very important target of miR-29a-3p: underexpression 
of miR-29a-3p affects neurodegenerative processes by enhancing 
neuronal NAV3 expression in AD brains (Shioya et al., 2010). The 
potentially important pathogenetic role of miR-130b-3p in VaD 
is suggested by the biomolecular functions of its targets. EDN1 is 
the most powerful among the three members of the endothelin 
family (EDN1, EDN2, and EDN3) (Maguire and Davenport, 
2014). They are synthesized mainly in the endothelium and per-
form a key role in the homeostasis of the vascular system, acting 
as powerful vasoconstrictor agents (Agapitov and Haynes, 2002). 
Endothelins are primarily involved in cerebral circulation deficits 
and in the pathogenesis of many heart and circulatory system 
diseases (Agapitov and Haynes, 2002). Another relevant target 
of miR-130b-3p is ENPP5: it is highly expressed in the brain 
and plays an important role in communication among neuronal 
cells (Ohe et al., 2003). Its overexpression is important after the 
onset of neuronal damage, when CNS attempts to reestablish lost 
neuronal connections (Schinelli, 2006). Both EDN1 and ENPP5 
functions would agree with potential involvement of miR-
130b-3p underexpression in contributing to neurodegeneration. 
It is worth to stress that miR-130b-3p, downregulated in both 
VaD and AD with respect to NCs, was able to discriminate the 
two diseases with 70% of sensitivity and 46% of specificity, and its 
expression was negatively correlated with intellectual deteriora-
tion in AD. In Figure 5, the potential cellular pathways controlled 
by miR-10b*, miR-29a-3p, and 130b-3p are depicted, based on 
their interactions with targets reported above.
FigUre 5 | cellular pathways controlled by mir-10b* (a), mir-29a (B), and 130b-3p (c). APP, amyloid precursor protein; ECE, endothelin converting 
enzyme; p+, phosphorylation.
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cOnclUsiOn
Our study describes a set of non-invasive miRNA biomarkers, 
which are detectable in plasma of VaD patients, and could confer 
molecular precision and improve detection power of VaD diagno-
sis. The use of cmiRNAs as biomarkers should be effectively asso-
ciated with other traditional well validated markers of VaD (e.g., 
structural and molecular imaging). Further multicentric studies 
on larger cohorts of patients and on other NDs will be needed 
to verify the effective diagnostic and discriminatory power of 
miR-10b*, miR-29a-3p, and 130b-3p and other cmiRNAs in VaD 
and AD. Profiling of circulating ncRNAs in NDs could have an 
important impact on clinical practice in Neuropsychiatry and also 
be exploited to improve our understanding of still partially char-
acterized molecular aspects of these phenotypes (Geekiyanage 
et al., 2012; Geaghan and Cairns, 2014).
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